Key Takeaways
- Vivitrol (extended-release naltrexone) is a once-monthly intramuscular injection that blocks opioid receptors for 28–30 days and is the only MAT medication FDA-approved for both opioid and alcohol use disorders.
- Unlike agonist therapies, Vivitrol is a full opioid antagonist with no abuse potential, no physical dependence risk, and non-controlled-substance status, but requires 7–14 days of verified opioid abstinence before initiation.
- The X:BOT trial demonstrated comparable relapse prevention outcomes between Vivitrol and Suboxone once initiated, though the detoxification requirement creates a significant induction barrier for the naltrexone pathway.
- Post-Vivitrol opioid sensitivity is dramatically heightened due to receptor upregulation, making missed injections or treatment discontinuation a period of extreme overdose risk requiring specific safety planning.
- For alcohol use disorder, naltrexone modulates the endogenous opioid reward system to reduce drinking pleasure and craving intensity, with the COMBINE study demonstrating significant reductions in heavy drinking days.
- Vivitrol costs approximately $1,500–$1,800 per injection at wholesale, but most insurance plans including Medi-Cal cover it, and the Alkermes co-pay savings program can reduce costs to as low as $5 per dose.
What Is Vivitrol and How Does It Differ from Other MAT Medications?
Vivitrol is the brand name for extended-release naltrexone, a once-monthly intramuscular injection that blocks opioid receptors for approximately 28 to 30 days per dose. Unlike Suboxone (buprenorphine/naloxone) and methadone, which are opioid agonists that activate receptors to suppress withdrawal and cravings, naltrexone is a full opioid antagonist — it binds tightly to mu-opioid receptors without activating them, effectively creating a pharmacological blockade that prevents any opioid from producing its characteristic effects. The FDA approved Vivitrol for the prevention of relapse to opioid dependence in 2010 and for the treatment of alcohol dependence in 2006, making it the only injectable MAT medication and the only MAT option approved for both opioid and alcohol use disorders.
The pharmacological distinction between antagonist and agonist therapy is fundamental to understanding which patients are best suited for Vivitrol. Because naltrexone blocks rather than activates opioid receptors, it produces no physical dependence, carries no potential for euphoria or abuse, and is not a controlled substance — eliminating the diversion concerns associated with methadone and buprenorphine. However, this same mechanism means that patients must be fully detoxified from all opioids before receiving their first injection, as administering naltrexone to someone with opioids still occupying their receptors would precipitate immediate, severe withdrawal. The required opioid-free period is a minimum of 7 to 14 days, confirmed by both patient report and a naloxone challenge test or negative urine drug screen.
The extended-release injectable formulation addresses one of the greatest challenges in addiction treatment: medication adherence. Oral naltrexone tablets have been available since the 1980s but have consistently demonstrated poor real-world effectiveness due to dismal adherence rates. By delivering naltrexone in a slow-release polymer microsphere formulation injected into the gluteal muscle, Vivitrol ensures therapeutic blood levels for a full month, eliminating the daily decision to take or skip the medication. This passive adherence model is one of Vivitrol's most compelling clinical advantages, particularly for patients in early recovery when motivation fluctuates and the risk of impulsive relapse is highest.
Who Is a Good Candidate for Vivitrol?
Identifying the ideal Vivitrol candidate requires careful clinical assessment of the patient's addiction history, current recovery stage, co-occurring conditions, and personal treatment preferences. The strongest candidates typically include individuals who have completed medically supervised detoxification and achieved at least 7 to 14 days of verified opioid abstinence, patients who are highly motivated to maintain abstinence and prefer a non-opioid treatment approach, those with concerns about the dependence potential of agonist therapies, individuals in the criminal justice system where agonist medications may face resistance, and patients with alcohol use disorder as a primary or co-occurring diagnosis.
Conversely, Vivitrol is generally not appropriate for patients who are currently physically dependent on opioids and unable to complete detoxification, those who require immediate stabilization that agonist therapies provide, individuals with active hepatic insufficiency or acute hepatitis, or patients who have demonstrated a clear need for the ongoing receptor activation that only agonist medications provide. Trust SoCal's clinical team in Orange County works closely with each patient to evaluate these factors through comprehensive intake assessments and shared decision-making conversations.
The landmark X:BOT trial (Extended-Release Naltrexone versus Buprenorphine-Naloxone for Opioid Treatment), published in The Lancet in 2018, found that once patients were successfully initiated on their respective medications, Vivitrol and Suboxone produced comparable relapse rates and treatment outcomes. However, the study also revealed a significant induction hurdle for Vivitrol: a substantial proportion randomized to naltrexone failed to complete detoxification and never received their first injection. This finding underscores the critical importance of robust detoxification support for patients pursuing the Vivitrol pathway.
The X:BOT trial published in The Lancet (2018) demonstrated that once successfully initiated, Vivitrol and Suboxone produced comparable relapse prevention outcomes. The primary challenge with Vivitrol is the detoxification requirement — making robust medical detox support essential for successful initiation.
Ideal Vivitrol Candidate Profile
Several clinical factors help identify patients who are most likely to succeed with Vivitrol-based treatment.
- Completed medically supervised detoxification with 7–14 days of verified opioid abstinence confirmed by naloxone challenge or negative urine screen.
- Strong personal motivation for abstinence-based recovery and preference for a non-opioid, non-controlled-substance treatment approach.
- Co-occurring alcohol use disorder that would benefit from naltrexone's dual FDA approval for both opioid and alcohol dependence.
- Criminal justice involvement where opioid agonist medications may face institutional barriers or patient preference aligns with antagonist therapy.
- History of adequate trials on agonist therapies that were discontinued due to side effects, preference, or clinical decision rather than inadequate response.
The Vivitrol Injection Process: What to Expect
The Vivitrol injection protocol involves several distinct clinical steps, beginning well before the actual injection. The pre-injection phase is the most critical: patients must be confirmed opioid-free for a minimum of 7 to 14 days to avoid precipitated withdrawal, which can be life-threatening with naltrexone. Verification methods include detailed patient history and timeline of last opioid use, urine drug screen negative for all opioids including fentanyl-specific testing, and when clinically indicated a naloxone challenge test in which a small dose of naloxone is administered and the patient is observed for 30 to 60 minutes. Only after opioid-free status is confirmed does the clinician proceed.
The injection itself is administered as a 380 mg dose of extended-release naltrexone delivered via deep intramuscular injection into the gluteal muscle, alternating sides monthly. The medication comes as a pre-packaged kit that must be stored in the refrigerator and brought to room temperature before injection. Patients should be advised that the injection site may be sore or tender for several days — this is normal and typically resolves within a week. Rare but serious injection site reactions, including tissue necrosis requiring surgical intervention, have been reported, and patients should contact their provider immediately if they experience worsening pain, swelling, or hardening at the site.
Following the injection, therapeutic naltrexone blood levels are maintained for approximately 28 to 30 days. Patients should schedule their next injection within 4 weeks to maintain continuous receptor blockade. One of the most dangerous periods for Vivitrol patients is after a missed injection: as naltrexone levels decline, opioid receptor sensitivity returns to baseline or may even be enhanced due to receptor upregulation, meaning that any return to opioid use carries a dramatically elevated overdose risk. Every Vivitrol patient must be educated about this risk and have a safety plan in place.
After a missed Vivitrol injection, opioid tolerance drops to near-zero levels. Any return to opioid use at previous doses carries an extreme risk of fatal overdose. If you miss an injection, contact your treatment provider immediately and do not use opioids at any dose until you have been medically reassessed.
Vivitrol for Alcohol Use Disorder
While much of the public conversation around Vivitrol focuses on opioid addiction, the medication's FDA approval for alcohol dependence actually predates its opioid indication by four years. Naltrexone's mechanism in alcohol use disorder modulates the endogenous opioid system that mediates alcohol's reinforcing effects, reducing the pleasurable reward from drinking and diminishing the craving-driven urge to consume alcohol. The COMBINE study, a landmark NIAAA-funded trial published in JAMA in 2006, demonstrated that naltrexone combined with medical management significantly reduced heavy drinking days compared to placebo.
For patients with alcohol use disorder, Vivitrol does not require a prolonged abstinence period before initiation — unlike the opioid indication. Patients can begin Vivitrol while still actively drinking or shortly after their last drink, though most clinicians prefer to initiate after at least a brief abstinence period. The medication works most effectively when combined with behavioral interventions such as motivational enhancement therapy, cognitive behavioral relapse prevention, and involvement in mutual support communities.
The dual-indication nature of Vivitrol makes it especially valuable for patients with co-occurring opioid and alcohol use disorders, an increasingly common clinical presentation. Polysubstance use involving both opioids and alcohol creates multiplicative overdose risk. A single medication that simultaneously addresses cravings and blocks the reinforcing effects of both substances offers a uniquely efficient pharmacological solution. At Trust SoCal, our Orange County clinicians carefully evaluate patients for co-occurring substance use disorders during intake and consider Vivitrol's dual utility in treatment planning.
Vivitrol for Alcohol: Key Points
Naltrexone has a well-established evidence base for alcohol use disorder treatment, with unique clinical advantages.
- FDA approved for alcohol dependence since 2006, with the COMBINE study demonstrating significant reductions in heavy drinking days compared to placebo.
- Does not require prolonged abstinence before initiation for alcohol use disorder, unlike the 7–14 day opioid-free requirement for OUD.
- Reduces alcohol craving by modulating the endogenous opioid reward system rather than directly blocking alcohol's pharmacological effects.
- Most effective when combined with behavioral interventions including motivational enhancement therapy and cognitive behavioral relapse prevention.
- Uniquely valuable for patients with co-occurring opioid and alcohol use disorders due to its dual FDA-approved indications.
Cost, Insurance Coverage, and Accessing Vivitrol
One of the most frequently cited barriers to Vivitrol treatment is its cost. The wholesale acquisition cost of each monthly injection is approximately $1,500 to $1,800, making it significantly more expensive per month than generic buprenorphine/naloxone or methadone dispensing fees. However, Vivitrol eliminates daily clinic visit costs, reduces monitoring burden, and its guaranteed adherence model may reduce downstream healthcare costs associated with relapse, emergency department visits, and repeated treatment episodes.
Insurance coverage has expanded considerably. Most commercial plans, Medicare Part B (as a physician-administered injectable), and Medicaid programs including Medi-Cal now cover Vivitrol, though prior authorization is commonly required. The Mental Health Parity and Addiction Equity Act mandates equitable coverage. Alkermes, the manufacturer, offers a patient assistance program (the VIVITROL Co-Pay Savings Program) that can reduce out-of-pocket costs to as low as $5 per injection for commercially insured patients.
For Orange County residents, Trust SoCal provides comprehensive insurance verification and financial counseling as part of our admissions process. Our team at (949) 280-8360 can determine specific coverage, navigate prior authorization, connect patients with manufacturer assistance, and explore alternative funding for uninsured patients. We administer Vivitrol injections on-site as part of our integrated MAT program, ensuring each injection includes a clinical check-in, urine drug screen, and behavioral health review.
Ask about the Alkermes VIVITROL Co-Pay Savings Program, which can reduce out-of-pocket costs to as low as $5 per injection for commercially insured patients. Trust SoCal admissions at (949) 280-8360 can also help navigate prior authorization and manufacturer assistance programs.
Integrating Vivitrol with Comprehensive Recovery Programming
Vivitrol provides a powerful pharmacological foundation, but its effectiveness is maximized within a comprehensive treatment program addressing the behavioral, psychological, and social dimensions of addiction. The monthly injection model creates a natural clinical rhythm: each 4-week cycle begins with the injection visit (doubling as a medical check-in), proceeds through weekly therapy sessions and recovery support, and culminates in a pre-injection assessment evaluating progress and preparing for the next dose.
Behavioral health integration is particularly important for Vivitrol patients because, unlike agonist therapies, naltrexone does not provide pharmacological comfort or stabilization — it simply removes the option of getting high. Cognitive behavioral therapy helps patients identify and manage triggers, develop healthier response patterns, and build distress tolerance. Motivational interviewing reinforces intrinsic commitment to change, especially important during early months when sobriety is accompanied by grief for the lost substance relationship.
At Trust SoCal, our Orange County programs offer Vivitrol within a fully integrated continuum of care that includes individual therapy, group counseling, family therapy, trauma-informed interventions, holistic wellness programming, and aftercare planning. We work collaboratively with each patient to establish measurable recovery goals — improved relationships, stable housing, meaningful employment, physical health optimization, and a growing sense of purpose beyond addiction.
Safety Considerations and Overdose Prevention
One of the most critical safety considerations is the risk of opioid overdose following treatment discontinuation or a missed injection. Naltrexone triggers mu-opioid receptor upregulation, increasing the number and sensitivity of opioid receptors during prolonged blockade. When naltrexone levels decline, this results in dramatically heightened opioid sensitivity, meaning previously tolerated doses could now be lethal. Every Vivitrol patient must be thoroughly educated about this risk during informed consent and at every subsequent injection visit.
The clinical team must also prepare patients for the scenario of attempting to override the naltrexone blockade by using large amounts of opioids. At therapeutic levels, typical opioid doses produce no effect, potentially tempting dose escalation. This can result in fatal respiratory depression if opioid quantity exceeds blockade capacity or if timing coincides with waning levels near the end of the injection cycle. Patients must understand that attempting to overcome the blockade is extremely dangerous.
Emergency medical situations present unique considerations: if a patient on Vivitrol requires opioid analgesia, standard doses will be ineffective due to receptor blockade. Emergency physicians must be informed so alternative strategies — regional anesthesia, non-opioid analgesics, or in extreme cases carefully titrated high-dose opioids with continuous ICU monitoring — can be employed. All Vivitrol patients should carry a medical alert card or wear a bracelet indicating their naltrexone status.
Vivitrol patients must carry a medical alert card or wear a bracelet identifying their naltrexone treatment. In emergencies requiring pain management, standard opioid doses will be ineffective due to receptor blockade, and healthcare providers need this information for alternative analgesic strategies.
Medical Review Board, MD, ABAM
Medical Director & Reviewer
